DUPA |
| Catalog No.GC34563 |
Le DUPA, qui appartient À une classe de glutamate urées, est utilisé comme fragment de ciblage dans un conjugué médicamenteux pour administrer sélectivement des médicaments cytotoxiques aux cellules cancéreuses de la prostate.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 302941-52-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells[1][2].
DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer[1]. The DUPA-indenoisoquinoline conjugate exhibits an IC50 in the low nanomolar range in 22RV1 cell cultures[2].
The DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity, as determined by loss of body weight and death of treated mice[2].
[1]. Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80. [2]. Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *